Transforming Radiotherapy Transforming Radiotherapy with with Dismutase Mimetics Dismutase Mimetics January 2021 Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statement

with Dismutase Mimetics Dismutase Mimetics January 2021Exhibit 99.1 Transforming Radiotherapy Transforming Radiotherapy with with Dismutase Mimetics Dismutase Mimetics January 2021

Disclaimers and Forward-Looking Statements Certain information contained

in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera's own internal estimates and research. While Galera

believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-

party sources. While Galera believes its internal research is reliable, such research has not been verified by any independent source. This presentation contains "forward-looking statements" within the meaning of the Private Securities

Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future

plans and strategies, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of operations and financial position,

business strategy, the safety, efficacy, regulatory and clinical progress, and therapeutic potential of current and prospective product candidates, plans and timing for the commencement of and the release of data from clinical trials, our plans to

prepare for commercialization and a US launch, the anticipated direct and indirect impact of COVID-19 on Galera's business and operations, planned clinical trials and preclinical activities, potential product approvals and related commercial

opportunity, current and prospective collaborations, and timing and likelihood of success, plans and objectives of management for future operations, are forward-looking statements. The words "may," "will,"

"should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict,"

"potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The

information in this presentation, including without limitation the forward-looking statements contained herein, represent our views as of the date of this presentation. Although we believe the expectations reflected in such forward-looking

statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not

plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about

the accuracy of any such forward-looking statements. The forward-looking statements in this presentation involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and

uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, our reliance on third parties over which we may not always have full control, and

other important risks and uncertainties that are described in Galera's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the U.S. Securities and Exchange Commission (SEC), Annual Report on Form 10-K for

the year ended December 31, 2019 and Galera's other filings with the SEC. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Whenever the Company uses the

terms "transform radiotherapy" or "transforming radiotherapy" in this presentation, it is referring to its mission statement.Disclaimers and Forward-Looking Statements Certain information contained in this presentation and

statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera's own internal estimates and research. While Galera believes these third-party

sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third- party sources. While Galera

believes its internal research is reliable, such research has not been verified by any independent source. This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of

1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our

clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of operations and financial position, business strategy, the safety,

efficacy, regulatory and clinical progress, and therapeutic potential of current and prospective product candidates, plans and timing for the commencement of and the release of data from clinical trials, our plans to prepare for commercialization

and a US launch, the anticipated direct and indirect impact of COVID-19 on Galera's business and operations, planned clinical trials and preclinical activities, potential product approvals and related commercial opportunity, current and prospective

collaborations, and timing and likelihood of success, plans and objectives of management for future operations, are forward-looking statements. The words "may," "will," "should," "expect,"

"plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or

"continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The information in this

presentation, including without limitation the forward-looking statements contained herein, represent our views as of the date of this presentation. Although we believe the expectations reflected in such forward-looking statements are reasonable, we

can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or

revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such

forward-looking statements. The forward-looking statements in this presentation involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause

actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, our reliance on third parties over which we may not always have full control, and other important risks and

uncertainties that are described in Galera's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the U.S. Securities and Exchange Commission (SEC), Annual Report on Form 10-K for the year ended December

31, 2019 and Galera's other filings with the SEC. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Whenever the Company uses the terms "transform

radiotherapy" or "transforming radiotherapy" in this presentation, it is referring to its mission statement.

Superoxide Dismutase Mimetics - Vision Rapid elimination of Over

half of cancer patients Increase H O in tumors 2 2 Superoxide (O ) 2 receive radiotherapy IMRT SBRT 1, 2 as part of their care Intensity Modulated Stereotactic Body RT RT Potential to Reduce Toxicity Potential to Increase Efficacy Severe Oral

Mucositis Esophagitis Pancreatic Cancer Lung Cancer Locally Advanced Head & Neck Cancer NSC Lung Cancer Locally Advanced Transforming Radiotherapy (SOM in HNC) (NSCLC) (LAPC) (LANSCLC) with Dismutase Mimetics Phase 3 Phase 2 Phase 2b Phase 1b/2

ROMAN AESOP GRECO-2 GRECO-1 Normal tissue toxicity limits Radiotherapy is SoC for many local tumors but need remains for greater efficacy optimal radiotherapy treatment of tumor 1 Delaney G, Jacob S, Featherstone C, Barton M. The role of

radiotherapy in cancer treatment Cancer. 2005;104:1129-1137 3 2 Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11:239-253Superoxide Dismutase Mimetics - Vision Rapid elimination

of Over half of cancer patients Increase H O in tumors 2 2 Superoxide (O ) 2 receive radiotherapy IMRT SBRT 1, 2 as part of their care Intensity Modulated Stereotactic Body RT RT Potential to Reduce Toxicity Potential to Increase Efficacy Severe

Oral Mucositis Esophagitis Pancreatic Cancer Lung Cancer Locally Advanced Head & Neck Cancer NSC Lung Cancer Locally Advanced Transforming Radiotherapy (SOM in HNC) (NSCLC) (LAPC) (LANSCLC) with Dismutase Mimetics Phase 3 Phase 2 Phase 2b Phase

1b/2 ROMAN AESOP GRECO-2 GRECO-1 Normal tissue toxicity limits Radiotherapy is SoC for many local tumors but need remains for greater efficacy optimal radiotherapy treatment of tumor 1 Delaney G, Jacob S, Featherstone C, Barton M. The role of

radiotherapy in cancer treatment Cancer. 2005;104:1129-1137 3 2 Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11:239-253

Corporate Highlights Phase 3 ROMAN Results with Avasopasem Reducing IMRT

Severe Oral Mucositis in Head & Neck Cancer Toxicity Robust Phase 2b data Breakthrough Therapy Designation Complete Survival Results from Pancreatic Cancer Pilot Increasing SBRT 1-Year data on all patients from

randomized LAPC trial Efficacy Promising data from this trial was presented in 2020 Large Market Opportunities with High Unmet Medical Need ~40 reps for Planning the 4,000 radiation US Building commercial team for US launch of

avasopasem Launch oncologists in U.S. US Target Patient Population of Lead Indication is 42,000 4Corporate Highlights Phase 3 ROMAN Results with Avasopasem Reducing IMRT Severe Oral Mucositis in Head & Neck Cancer Toxicity

Robust Phase 2b data Breakthrough Therapy Designation Complete Survival Results from Pancreatic Cancer Pilot Increasing SBRT 1-Year data on all patients from randomized LAPC trial Efficacy Promising data from this trial was

presented in 2020 Large Market Opportunities with High Unmet Medical Need ~40 reps for Planning the 4,000 radiation US Building commercial team for US launch of avasopasem Launch oncologists in U.S. US Target Patient Population of Lead

Indication is 42,000 4

Clinical Stage Pipeline Phase 1 Phase 2 Phase 3 Next Anticipated

Milestone 1a 1b 2a 2b ROMAN Topline Data Reducing SOM in Head & Neck Cancer avasopasem vs. placebo 2H 2021 RT Toxicity EUSOM Topline Data (1) SOM in Head & Neck Cancer avasopasem single-arm 2H 2021 IMRT AESOP Topline Data (2) Esophagitis in

NSCLC Combos avasopasem single-arm 1H 2022 LAPC Pilot 1 Year Follow-up (3) Pancreatic Cancer Increasing GC4419 vs. placebo 2H 2021 RT st GRECO-1 1 Stage Data (4) Efficacy NSC Lung Cancer GC4711 vs. placebo 1H 2022 SBRT GRECO-2 Initiate Trial

Pancreatic Cancer GC4711 vs. placebo 1H 2021 Combos COVID Pilot Topline Data COVID-19 Critically Ill Patients avasopasem vs. placebo 1H 2021 (1) EUSOM is a single-arm multi-center trial evaluating the safety of avasopasem in patients with HNC in

Europe. (2) Phase 2a trial in patients with lung cancer building on avasopasem safety and tolerability findings from SOM trials in patients with HNC. (3) This first SBRT combination trial used GC4419 (avasopasem). Observations from this pilot trial

have been used to guide development of GC4711 to assess anti-cancer efficacy in combination with SBRT. 5 (4) Two stage trial with first stage to assess anti-cancer efficacy of SBRT +/- GC4711 and the second stage to assess anti-cancer efficacy of

SBRT and checkpoint inhibitor +/- GC4711.Clinical Stage Pipeline Phase 1 Phase 2 Phase 3 Next Anticipated Milestone 1a 1b 2a 2b ROMAN Topline Data Reducing SOM in Head & Neck Cancer avasopasem vs. placebo 2H 2021 RT Toxicity EUSOM Topline Data

(1) SOM in Head & Neck Cancer avasopasem single-arm 2H 2021 IMRT AESOP Topline Data (2) Esophagitis in NSCLC Combos avasopasem single-arm 1H 2022 LAPC Pilot 1 Year Follow-up (3) Pancreatic Cancer Increasing GC4419 vs. placebo 2H 2021 RT st

GRECO-1 1 Stage Data (4) Efficacy NSC Lung Cancer GC4711 vs. placebo 1H 2022 SBRT GRECO-2 Initiate Trial Pancreatic Cancer GC4711 vs. placebo 1H 2021 Combos COVID Pilot Topline Data COVID-19 Critically Ill Patients avasopasem vs. placebo 1H 2021 (1)

EUSOM is a single-arm multi-center trial evaluating the safety of avasopasem in patients with HNC in Europe. (2) Phase 2a trial in patients with lung cancer building on avasopasem safety and tolerability findings from SOM trials in patients with

HNC. (3) This first SBRT combination trial used GC4419 (avasopasem). Observations from this pilot trial have been used to guide development of GC4711 to assess anti-cancer efficacy in combination with SBRT. 5 (4) Two stage trial with first stage to

assess anti-cancer efficacy of SBRT +/- GC4711 and the second stage to assess anti-cancer efficacy of SBRT and checkpoint inhibitor +/- GC4711.

Unique Technology Small Molecule Enzyme Mimetics Dismutase Mimic

human superoxide dismutase (SOD) enzymes Mimetics Rapidly convert superoxide (O ) to hydrogen peroxide (H O ) 2 2 2 Avasopasem (GC4419) O more damaging 2 GC4711 Shifts balance in normal & cancer cells to normal cells than from superoxide

to hydrogen peroxide cancer cells H O more toxic to 2 2 cancer cells than normal cells 6Unique Technology Small Molecule Enzyme Mimetics Dismutase Mimic human superoxide dismutase (SOD) enzymes Mimetics Rapidly convert superoxide (O )

to hydrogen peroxide (H O ) 2 2 2 Avasopasem (GC4419) O more damaging 2 GC4711 Shifts balance in normal & cancer cells to normal cells than from superoxide to hydrogen peroxide cancer cells H O more toxic to 2 2 cancer cells than normal cells

Galera's Dismutase Mimetics Native SOD Enzymes Native

Overexpression reduces RT toxicity SOD Large size, immunogenicity & short half-lives limit bioavailability Enzymes Inactivation/inhibition by reactive oxygen species Challenge: suitable small molecule dismutase mimetics Small

Fast catalytic rates & high selectivity for superoxide Molecule Firmly hold manganese in macrocyclic ring Mimetics Stable, safe & suitable for manufacturing Dismutase Mimetics Core Structure Pentaaza Macrocycles Small

Molecule Dismutase Mimetics with Attractive Drug Characteristics Speed Selectivity Stability Safety Synthesis Comparable to native SODs Interact with superoxide alone, Firmly hold Mn atom Well-tolerated Efficient & cost-effective 7 (2x10

molecules per sec) not other reactive oxygen species in macrocyclic ring preclinically and clinically manufacturing process 7Galera's Dismutase Mimetics Native SOD Enzymes Native Overexpression reduces RT toxicity SOD Large size,

immunogenicity & short half-lives limit bioavailability Enzymes Inactivation/inhibition by reactive oxygen species Challenge: suitable small molecule dismutase mimetics Small Fast catalytic rates & high selectivity for

superoxide Molecule Firmly hold manganese in macrocyclic ring Mimetics Stable, safe & suitable for manufacturing Dismutase Mimetics Core Structure Pentaaza Macrocycles Small Molecule Dismutase Mimetics with Attractive Drug

Characteristics Speed Selectivity Stability Safety Synthesis Comparable to native SODs Interact with superoxide alone, Firmly hold Mn atom Well-tolerated Efficient & cost-effective 7 (2x10 molecules per sec) not other reactive oxygen species in

macrocyclic ring preclinically and clinically manufacturing process 7

Reducing IMRT Toxicity (Intensity Modulated Radiotherapy)Reducing IMRT

Toxicity (Intensity Modulated Radiotherapy)

Reducing IMRT Toxicity - Large Unmet Medical Need Phase 1 Phase 2

Phase 3 Next Anticipated Milestone 1a 1b 2a 2b ROMAN Topline Data Reducing SOM in Head & Neck Cancer avasopasem vs. placebo 2H 2021 RT Toxicity EUSOM Topline Data (1) SOM in Head & Neck Cancer avasopasem single-arm 2H 2021 IMRT AESOP Topline

Data (2) Esophagitis in NSCLC Combos avasopasem single-arm 1H 2022 US Target Patient Population Cancer Annual Target Subset Patients US Incidence Indication Market Head & Neck Severe Oral Locally 65,000 42,000 Cancer Mucositis Advanced Potential

NSC Lung Central 175,000 Esophagitis 50,000 Cancer Tumors (1) EUSOM is a single-arm multi-center trial evaluating the safety of avasopasem in patients with HNC in Europe. 9 (2) Phase 2a trial in patients with lung cancer building on avasopasem

safety and tolerability findings from SOM trials in patients with HNC.Reducing IMRT Toxicity - Large Unmet Medical Need Phase 1 Phase 2 Phase 3 Next Anticipated Milestone 1a 1b 2a 2b ROMAN Topline Data Reducing SOM in Head & Neck Cancer

avasopasem vs. placebo 2H 2021 RT Toxicity EUSOM Topline Data (1) SOM in Head & Neck Cancer avasopasem single-arm 2H 2021 IMRT AESOP Topline Data (2) Esophagitis in NSCLC Combos avasopasem single-arm 1H 2022 US Target Patient Population Cancer

Annual Target Subset Patients US Incidence Indication Market Head & Neck Severe Oral Locally 65,000 42,000 Cancer Mucositis Advanced Potential NSC Lung Central 175,000 Esophagitis 50,000 Cancer Tumors (1) EUSOM is a single-arm multi-center trial

evaluating the safety of avasopasem in patients with HNC in Europe. 9 (2) Phase 2a trial in patients with lung cancer building on avasopasem safety and tolerability findings from SOM trials in patients with HNC.

SEVERE Severe Oral Mucositis in HNC - Large Unmet Medical Need

Large Target Large Target Patient Patient Population Population (42K) (42K) SOM SOM Can Can Have Devastating Complications Have Devastating Complications Lack Lack of Efficacy with of Efficacy with Current Current Treatments Treatments MASCC / ISOO

Guidelines for HNC OM WHO Grading Scale Dehydration & 1 No ulcers Recommended for HNC ~65,000 new HNC Erythema and soreness Treatment Approach Malnutrition 42,000 OM due to RT? patients in US/Year receive Often requiring PEG 2

Ulcers Basic oral care IMRT Able to eat a solid diet tube feeding ~65% get IMRT & 3 Ulcers Anti-microbials, coating cisplatin as Requires a liquid diet Pain agents, anesthetics, & standard-of-care Often severe

pain analgesics (0.2% morphine 4 Ulcers Unable to eat or drink mouthwash) requiring opioids ~70% of patients get Anti-inflammatories, SOM (can't eat) ? benzydamine Treatment interruption Each week of treatment delay

~20-30% get Gr. 4 Low level laser & other ? decreases tumor control by >10% light therapy (can't eat or drink) Cryotherapy for Increased economic burden No approved drug 5-FU chemotherapy OM Dx ~$32,000 in

additional medical available Natural & other agents expenses in first 6 months from RT start 10SEVERE Severe Oral Mucositis in HNC - Large Unmet Medical Need Large Target Large Target Patient Patient Population Population (42K) (42K)

SOM SOM Can Can Have Devastating Complications Have Devastating Complications Lack Lack of Efficacy with of Efficacy with Current Current Treatments Treatments MASCC / ISOO Guidelines for HNC OM WHO Grading Scale Dehydration & 1 No ulcers

Recommended for HNC ~65,000 new HNC Erythema and soreness Treatment Approach Malnutrition 42,000 OM due to RT? patients in US/Year receive Often requiring PEG 2 Ulcers Basic oral care IMRT Able to eat a solid diet tube feeding

~65% get IMRT & 3 Ulcers Anti-microbials, coating cisplatin as Requires a liquid diet Pain agents, anesthetics, & standard-of-care Often severe pain analgesics (0.2% morphine 4 Ulcers Unable to eat or drink mouthwash)

requiring opioids ~70% of patients get Anti-inflammatories, SOM (can't eat) ? benzydamine Treatment interruption Each week of treatment delay ~20-30% get Gr. 4 Low level laser & other ? decreases tumor control by